Benzinga | Dec 8, 2020 07:05AM EST

uniQure Announces Data From the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B Met The First Primary Endpoint

~ First primary endpoint in study met with mean Factor IX activity of 37% of normal at 26 weeks ~

~ Data show 91% reduction in reported bleeds requiring treatment, with 87% of patients reporting no such bleeds during the 26 weeks after dosing ~

~ Durable increases in Factor IX activity maintained for up to 18 months irrespective of pre-existing neutralizing antibodies ~

~ Etranacogene dezaparvovec was well-tolerated with no treatment-related serious adverse events ~

~ uniQure to host investor webcast today at 5:00 p.m. ET ~